Table 2 Univariate and multivariate analyses of overall survival
Univariate | Multivariate | ||
|---|---|---|---|
P value | OR (95% CI) | P value | |
Menopausal status | |||
Postmenopausal Premenopausal | 0.52 | - | - |
ER status | |||
Positive | 0.26 | - | - |
Negative | |||
PR status | |||
Negative | 0.47 | - | - |
Positive | |||
HER2 status | |||
Negative | 0.30 | - | - |
Positive | |||
Metastatic site | |||
Bone | 0.01 | 1 | 0.04 |
Visceral | 2.6 (1.0-6.8) | 0.05 | |
Both | 3.2 (1.3-8.2) | 0.01 | |
Number of metastatic sites | |||
One site Multiple sites | 0.01 | Not significant | - |
Disease-free interval | |||
≤12 months | 0.12 | - | - |
>12 months | |||
CTC positivity | |||
<5 cells | 0.00 | 1 | <0.01 |
≥5 cells | 2.7 (1.6-4.2)a | ||
Subtype | |||
'Luminal' | 0.09 | 1 | 0.02 |
HER2-positive | 0.9 (0.4-2.0) | 0.84 | |
Triple-negative | 2.1 (1.2-3.8) | 0.00 | |